Epstein-Barr virus nuclear antigen 1 peptide-MHC class I complex (EBNA1-MHC I complex)

The Epstein-Barr virus nuclear antigen 1 (EBNA1) peptide-MHC class I complex is a critical immunological target for treating EBV-associated malignancies and lymphoproliferative disorders. EBNA1 is a multifunctional viral protein essential for the replication, segregation, and maintenance of the EBV episome within host cells, and it is uniquely expressed in all EBV-related latency patterns. While EBNA1 contains a Gly-Ala repeat domain that inhibits its own proteasomal degradation to evade immune detection, specific peptide fragments are successfully processed and presented on MHC class I molecules (such as HLA-A*02:01) on the surface of infected cells. Therapeutic strategies targeting these EBNA1-derived epitopes include adoptive T-cell therapies, such as tabelecleucel, and the development of T-cell receptor (TCR)-like antibodies or TCR-engineered T-cells. These therapies aim to bypass the virus's immune evasion mechanisms by specifically recognizing the EBNA1 pMHC complex, thereby triggering a directed cytotoxic immune response against EBV-positive tumor cells. This target is particularly relevant in diseases like nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder, where EBV plays a primary oncogenic role.

Other names

EBV EBNA1-derived peptide epitopes presented on MHC class IEBNA1-HLA class I complexEBNA1 pMHCEpstein-Barr nuclear antigen 1 epitopes

Targeting of the peptide-MHC complex by T-cell receptors (TCRs) or TCR-mimetic molecules to induce T-cell mediated lysis of EBV-infected or malignant cells.